This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (36)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Cardiovascular System  • Women's Health  • Menopause  • Cardiovascular Disease/ Myocardial Infarction  • Alert me on articles by topic  Social Bookmarking   What's this?

Results From 2 Large Clinical Trials

Arch Intern Med. 2004;164:482-484.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

INTRODUCTION

Despite observational data suggesting that hormone therapy (HT) decreases the risk of coronary heart disease (CHD) in healthy postmenopausal women,¹ 2 large, randomized controlled trials that evaluated older postmenopausal women with² or without³ established CHD observed an increased risk of early events in women taking HT. In both of these trials 0.625 mg of oral conjugated equine estrogens (CEE) was used, combined continuously with 2.5 mg of medroxyprogesterone acetate (MPA), and both trials found an increased risk of events within the first year.³ However, in the Women's Health Initiative (WHI) trial, women with severe menopausal symptoms were excluded from participation and only one third of the participants receiving active treatment were younger than 60 years (average age, 63 years). Because most women use HT for symptom relief in their early menopausal years, understanding early CHD risk in the younger postmenopausal population is important. Therefore, the incidence of CHD events was . . . [Full Text of this Article]

STUDY METHODS

STUDY FINDINGS

CONCLUSIONS

Rogerio A. Lobo, MD
Columbia University College of Physicians & Surgeons
622 W 168th St
New York, NY 10032
(e-mail: ral35@columbia.edu)

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Menopause, Hormones, and Cardiovascular Vulnerability in Women
William B. Kannel and Daniel Levy
Arch Intern Med. 2004;164(5):479-481.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Efficacy, Safety, and Tolerability of Low-Dose Hormone Therapy in Managing Menopausal Symptoms
Langer
J Am Board Fam Med 2009;22:563-573.
ABSTRACT | FULL TEXT  

Invited Commentary: Hormone Therapy and Risk of Coronary Heart Disease Why Renew the Focus on the Early Years of Menopause?
Manson and Bassuk
Am J Epidemiol 2007;166:511-517.
ABSTRACT | FULL TEXT  

Historical Perspectives in Postmenopausal Hormone Therapy: Defining the Right Dose and Duration
Warren
Mayo Clin Proc. 2007;82:219-226.
ABSTRACT | FULL TEXT  

Premature Ovarian Failure in Cancer Survivors: New Insights, Looming Concerns.
Chen and Manson
JNCI J Natl Cancer Inst 2006;98:880-881.
FULL TEXT  

Controversies regarding hormone therapy: Insights from inflammation and hemostasis
Koh and Yoon
Cardiovasc Res 2006;70:22-30.
ABSTRACT | FULL TEXT  

Menopausal complaints, oestrogens, and heart disease risk: an explanation for discrepant findings on the benefits of post-menopausal hormone therapy
van der Schouw and Grobbee
Eur Heart J 2005;26:1358-1361.
ABSTRACT | FULL TEXT